Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I HIOC with Pemetrexed and Cisplatin for MPM
NCT02838745Phase 1Terminated
- Sponsor
- Baylor College of Medicine
- Start
- Sep 2016
- Primary completion
- Sep 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of pemetrexed in malignant pleural mesothelioma (MPM) (2 arms), sponsored by Baylor College of Medicine. Primary endpoint: Dose-Limiting Toxicity at 4 weeks. Started Sep 2016; status: terminated.
02
Drugs
pemetrexed
03
Conditions
malignant pleural mesothelioma (MPM)
Beyond the preview
Go deeper on NCT02838745.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02838745.